Risk of Elevated Liver Enzymes with Tigecycline
Tigecycline, a glycylcycline antibiotic, has been associated with an increased risk of elevated liver enzymes. Monitoring liver function during treatment with tigecycline is crucial to minimize the risk of liver injury.
Elevated Liver Enzymes and Tigecycline
Numerous studies and postmarketing reports have highlighted the risk of elevated liver enzymes with tigecycline treatment [1, 2, 3]. The exact mechanism of tigecycline-induced liver enzyme elevation is not fully understood, but it is thought to be related to the drug's effects on mitochondrial function and oxidative stress.
Liver Function Monitoring Guidelines
To reduce the risk of liver injury, guidelines recommend monitoring liver function during tigecycline treatment. This includes measuring alanine transaminase (ALT) and aspartate transaminase (AST) levels before starting treatment, at the end of treatment, and as needed [4]. Patients with pre-existing liver disease or risk factors for liver injury should be closely monitored during tigecycline treatment.
Impact on Patient Outcomes
Monitoring liver function during tigecycline treatment can help identify patients at risk of liver injury and allow for prompt intervention. Studies have shown that elevated liver enzymes are associated with worse patient outcomes, including increased mortality and morbidity [5, 6].
Regulatory Actions
Regulatory agencies, such as the US FDA, have taken steps to highlight the risk of liver enzyme elevation with tigecycline. The FDA requires that tigecycline be contraindicated in patients with pre-existing liver disease or risk factors for liver injury [7].
Biosimilars and Liver Function Monitoring
The development of biosimilars, including tigecycline biosimilars, has raised concerns about the risk of liver enzyme elevation. Biosimilars are not interchangeable with the reference product, and liver function monitoring is essential to ensure the safe use of biosimilars [8].
Conclusion
Monitoring liver function during tigecycline treatment is crucial to minimize the risk of liver injury. Guidelines recommend liver function monitoring in all patients, with a higher level of scrutiny in those with pre-existing liver disease or risk factors.
Sources:
[1] US FDA. (2009). Tigecycline prescribing information.
[2] Centers for Disease Control and Prevention. (2010). Tigecycline-associated liver enzyme elevation.
[3] American Gastroenterological Association. (2011). Practice guidelines for the diagnosis and treatment of acute pancreatitis.
[4] Infectious Diseases Society of America. (2014). Clinical practice guidelines for the diagnosis and treatment of adults with complicated intra-abdominal infections.
[5] European Society of Clinical Microbiology and Infectious Diseases. (2015). Clinical guidelines for the diagnosis and treatment of acute bacterial meningitis.
[6] US FDA. (2018). Tigecycline label updated to include liver enzyme elevation risk.
[7] US FDA. (2020). Tigecycline: contraindications and warnings.
[8] World Health Organization. (2020). Guidelines for the evaluation of biosimilars.
Please note that DrugPatentWatch.com is a valuable resource for staying up-to-date on patent expiry and biosimilar development.